Literature DB >> 17922664

Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis.

Henghe Tian1, Bruce N Cronstein.   

Abstract

Methotrexate has been widely used for the treatment of rheumatoid arthritis (RA). The mechanisms of action of methotrexate are complex. Developed as a folic acid analogue, methotrexate inhibits purine and pyrimidine synthesis, which accounts for its efficacy in the therapy of cancer as well as for some of its toxicities. Recently, many studies have focused on the adenosine-mediated antiinflammatory effects of methotrexate. Certain aspects of methotrexate toxicities are also attributed to adenosine release. A better understanding of the mechanisms of action and toxicities of methotrexate will direct clinicians in their treatment approach and toxicity monitoring. Toward that objective, the latest developments in the pharmacokinetics, mechanism of action, pharmacogenetics, and toxicity of methotrexate are herein discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922664

Source DB:  PubMed          Journal:  Bull NYU Hosp Jt Dis        ISSN: 1936-9719


  105 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease.

Authors:  Clifton O Bingham
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

Review 3.  Chronic Chikungunya Arthritis and Rheumatoid Arthritis: What They Have in Common.

Authors:  J Kennedy Amaral; Joshua B Bilsborrow; Robert T Schoen
Journal:  Am J Med       Date:  2019-11-06       Impact factor: 4.965

Review 4.  Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Authors:  Heinrike Schmeling; Gerd Horneff; Susanne M Benseler; Marvin J Fritzler
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

5.  1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis.

Authors:  Elizabeth Pigott; James B DuHadaway; Alexander J Muller; Susan Gilmour; George C Prendergast; Laura Mandik-Nayak
Journal:  Autoimmunity       Date:  2014-05-06       Impact factor: 2.815

6.  Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP.

Authors:  Rakesh K Singh; Leon van Haandel; Daniel P Heruth; Shui Q Ye; J Steven Leeder; Mara L Becker; Ryan S Funk
Journal:  J Pharmacol Exp Ther       Date:  2018-02-02       Impact factor: 4.030

7.  The urinary excretion of an organic anion transporter as an early biomarker of methotrexate-induced kidney injury.

Authors:  María J Severin; Mara S Trebucobich; Patricia Buszniez; Anabel Brandoni; Adriana M Torres
Journal:  Toxicol Res (Camb)       Date:  2016-01-07       Impact factor: 3.524

Review 8.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.

Authors:  Glen S Hazlewood; Cheryl Barnabe; George Tomlinson; Deborah Marshall; Daniel J A Devoe; Claire Bombardier
Journal:  Cochrane Database Syst Rev       Date:  2016-08-29

9.  Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2009-07-16       Impact factor: 5.156

10.  Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy.

Authors:  Carole L Galligan; Janet C Siebert; Katherine A Siminovitch; Edward C Keystone; Vivian Bykerk; Omar D Perez; Eleanor N Fish
Journal:  PLoS One       Date:  2009-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.